Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 36 entries
Sorted by: Best Match Show Resources per page
Esophageal carcinoma: surgery, radiotherapy, and chemotherapy.

Current opinion in gastroenterology

van Lanschot JJ, Aleman BM, Richel DJ.
PMID: 17033326
Curr Opin Gastroenterol. 2002 Jul;18(4):490-5. doi: 10.1097/00001574-200207000-00015.

Several new developments in the potentially curative therapy of esophageal cancer have drawn attention over the past year. There is a potential benefit of centralization of esophagectomies in dedicated centers. Early mucosal lesions are increasingly treated by local ablative...

Cite
van Lanschot JJ, Aleman BM, Richel DJ. Esophageal carcinoma: surgery, radiotherapy, and chemotherapy. Curr Opin Gastroenterol. 2002;18(4):490-5doi: 10.1097/00001574-200207000-00015.
van Lanschot, J. J., Aleman, B. M., & Richel, D. J. (2002). Esophageal carcinoma: surgery, radiotherapy, and chemotherapy. Current opinion in gastroenterology, 18(4), 490-5. https://doi.org/10.1097/00001574-200207000-00015
van Lanschot, J Jan B, et al. "Esophageal carcinoma: surgery, radiotherapy, and chemotherapy." Current opinion in gastroenterology vol. 18,4 (2002): 490-5. doi: https://doi.org/10.1097/00001574-200207000-00015
van Lanschot JJ, Aleman BM, Richel DJ. Esophageal carcinoma: surgery, radiotherapy, and chemotherapy. Curr Opin Gastroenterol. 2002 Jul;18(4):490-5. doi: 10.1097/00001574-200207000-00015. PMID: 17033326.
Copy Download .nbib Format: NLM
Development of a Reliable Surgical Quality Assurance System for 2-stage Esophagectomy in Randomized Controlled Trials.

Annals of surgery

Harris A, Butterworth J, Boshier PR, MacKenzie H, Tokunaga M, Sunagawa H, Mavroveli S, Ni M, Mikhail S, Yeh CC, Blencowe NS, Avery KNL, Hardwick R, Hoelscher A, Pera M, Zaninotto G, Law S, Low DE, van Lanschot JJB, Berrisford R, Barham CP, Blazeby JM, Hanna GB.
PMID: 32224728
Ann Surg. 2020 Mar 27; doi: 10.1097/SLA.0000000000003850. Epub 2020 Mar 27.

OBJECTIVE: The aim was to develop a reliable surgical quality assurance system for 2-stage esophagectomy. This development was conducted during the pilot phase of the multicenter ROMIO trial, collaborating with international experts.SUMMARY OF BACKGROUND DATA: There is evidence that...

Cite
Harris A, Butterworth J, Boshier PR, et al. Development of a Reliable Surgical Quality Assurance System for 2-stage Esophagectomy in Randomized Controlled Trials. Ann Surg. 2020;doi: 10.1097/SLA.0000000000003850.
Harris, A., Butterworth, J., Boshier, P. R., MacKenzie, H., Tokunaga, M., Sunagawa, H., Mavroveli, S., Ni, M., Mikhail, S., Yeh, C. C., Blencowe, N. S., Avery, K. N. L., Hardwick, R., Hoelscher, A., Pera, M., Zaninotto, G., Law, S., Low, D. E., van Lanschot, J. J. B., Berrisford, R., Barham, C. P., Blazeby, J. M., & Hanna, G. B. (2020). Development of a Reliable Surgical Quality Assurance System for 2-stage Esophagectomy in Randomized Controlled Trials. Annals of surgery, . https://doi.org/10.1097/SLA.0000000000003850
Harris, Alexander, et al. "Development of a Reliable Surgical Quality Assurance System for 2-stage Esophagectomy in Randomized Controlled Trials." Annals of surgery vol. (2020). doi: https://doi.org/10.1097/SLA.0000000000003850
Harris A, Butterworth J, Boshier PR, MacKenzie H, Tokunaga M, Sunagawa H, Mavroveli S, Ni M, Mikhail S, Yeh CC, Blencowe NS, Avery KNL, Hardwick R, Hoelscher A, Pera M, Zaninotto G, Law S, Low DE, van Lanschot JJB, Berrisford R, Barham CP, Blazeby JM, Hanna GB. Development of a Reliable Surgical Quality Assurance System for 2-stage Esophagectomy in Randomized Controlled Trials. Ann Surg. 2020 Mar 27; doi: 10.1097/SLA.0000000000003850. Epub 2020 Mar 27. PMID: 32224728.
Copy Download .nbib Format: NLM
Association between Paclitaxel Clearance and Tumor Response in Patients with Esophageal Cancer.

Cancers

Toxopeus ELA, de Man FM, Krak N, Biermann K, Nieuweboer AJM, Friberg LE, Oomen-de Hoop E, van Lanschot JJB, Shapiro J, Wijnhoven BPL, Mathijssen RHJ.
PMID: 30717316
Cancers (Basel). 2019 Feb 01;11(2). doi: 10.3390/cancers11020173.

Inter-individual variability in paclitaxel pharmacokinetics may play a role in the response to chemotherapy. Therefore, we studied the association between paclitaxel clearance and treatment response in patients with esophageal cancer. All patients who received paclitaxel (plus carboplatin) treatment for...

Cite
Toxopeus ELA, de Man FM, Krak N, et al. Association between Paclitaxel Clearance and Tumor Response in Patients with Esophageal Cancer. Cancers (Basel). 2019;11(2)doi: 10.3390/cancers11020173.
Toxopeus, E. L. A., de Man, F. M., Krak, N., Biermann, K., Nieuweboer, A. J. M., Friberg, L. E., Oomen-de Hoop, E., van Lanschot, J. J. B., Shapiro, J., Wijnhoven, B. P. L., & Mathijssen, R. H. J. (2019). Association between Paclitaxel Clearance and Tumor Response in Patients with Esophageal Cancer. Cancers, 11(2), . https://doi.org/10.3390/cancers11020173
Toxopeus, Eelke L A, et al. "Association between Paclitaxel Clearance and Tumor Response in Patients with Esophageal Cancer." Cancers vol. 11,2 (2019). doi: https://doi.org/10.3390/cancers11020173
Toxopeus ELA, de Man FM, Krak N, Biermann K, Nieuweboer AJM, Friberg LE, Oomen-de Hoop E, van Lanschot JJB, Shapiro J, Wijnhoven BPL, Mathijssen RHJ. Association between Paclitaxel Clearance and Tumor Response in Patients with Esophageal Cancer. Cancers (Basel). 2019 Feb 01;11(2). doi: 10.3390/cancers11020173. PMID: 30717316; PMCID: PMC6406317.
Copy Download .nbib Format: NLM
Interventions that Facilitate Shared Decision-Making in Cancers with Active Surveillance as Treatment Option: a Systematic Review of Literature.

Current oncology reports

Collée GE, van der Wilk BJ, van Lanschot JJB, Busschbach JJ, Timmermans L, Lagarde SM, Kranenburg LW.
PMID: 32725550
Curr Oncol Rep. 2020 Jul 28;22(10):101. doi: 10.1007/s11912-020-00962-3.

PURPOSE OF REVIEW: Medical decisions concerning active surveillance are complex, especially when evidence on superiority of one of the treatments is lacking. Decision aids have been developed to facilitate shared decision-making on whether to pursue an active surveillance strategy....

Cite
Collée GE, van der Wilk BJ, van Lanschot JJB, et al. Interventions that Facilitate Shared Decision-Making in Cancers with Active Surveillance as Treatment Option: a Systematic Review of Literature. Curr Oncol Rep. 2020;22(10):101doi: 10.1007/s11912-020-00962-3.
Collée, G. E., van der Wilk, B. J., van Lanschot, J. J. B., Busschbach, J. J., Timmermans, L., Lagarde, S. M., & Kranenburg, L. W. (2020). Interventions that Facilitate Shared Decision-Making in Cancers with Active Surveillance as Treatment Option: a Systematic Review of Literature. Current oncology reports, 22(10), 101. https://doi.org/10.1007/s11912-020-00962-3
Collée, G E, et al. "Interventions that Facilitate Shared Decision-Making in Cancers with Active Surveillance as Treatment Option: a Systematic Review of Literature." Current oncology reports vol. 22,10 (2020): 101. doi: https://doi.org/10.1007/s11912-020-00962-3
Collée GE, van der Wilk BJ, van Lanschot JJB, Busschbach JJ, Timmermans L, Lagarde SM, Kranenburg LW. Interventions that Facilitate Shared Decision-Making in Cancers with Active Surveillance as Treatment Option: a Systematic Review of Literature. Curr Oncol Rep. 2020 Jul 28;22(10):101. doi: 10.1007/s11912-020-00962-3. PMID: 32725550; PMCID: PMC7387328.
Copy Download .nbib Format: NLM
Active Surveillance Versus Immediate Surgery in Clinically Complete Responders After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Propensity Matched Study.

Annals of surgery

van der Wilk BJ, Noordman BJ, Neijenhuis LKA, Nieboer D, Nieuwenhuijzen GAP, Sosef MN, Henegouwen MIVB, Lagarde SM, Spaander MCW, Valkema R, Biermann K, Wijnhoven BPL, van der Gaast A, van Lanschot JJB, Doukas M, Nikkessen S, Luyer M, Schoon EJ, Roef MJ, van Lijnschoten I, Oostenbrug LE, Riedl RG, Gisbertz SS, Krishnadath KK, Bennink RJ, Meijer SL.
PMID: 31592898
Ann Surg. 2021 Dec 01;274(6):1009-1016. doi: 10.1097/SLA.0000000000003636.

OBJECTIVE: This study compared outcomes of patients with esophageal cancer and clinically complete response (cCR) after neoadjuvant chemoradiotherapy (nCRT) undergoing active surveillance or immediate surgery.BACKGROUND: Since nearly one-third of patients with esophageal cancer show pathologically complete response after nCRT...

Cite
van der Wilk BJ, Noordman BJ, Neijenhuis LKA, et al. Active Surveillance Versus Immediate Surgery in Clinically Complete Responders After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Propensity Matched Study. Ann Surg. 2021;274(6):1009-1016doi: 10.1097/SLA.0000000000003636.
van der Wilk, B. J., Noordman, B. J., Neijenhuis, L. K. A., Nieboer, D., Nieuwenhuijzen, G. A. P., Sosef, M. N., Henegouwen, M. I. V. B., Lagarde, S. M., Spaander, M. C. W., Valkema, R., Biermann, K., Wijnhoven, B. P. L., van der Gaast, A., van Lanschot, J. J. B., Doukas, M., Nikkessen, S., Luyer, M., Schoon, E. J., Roef, M. J., van Lijnschoten, I., Oostenbrug, L. E., Riedl, R. G., Gisbertz, S. S., Krishnadath, K. K., Bennink, R. J., Meijer, S. L. (2021). Active Surveillance Versus Immediate Surgery in Clinically Complete Responders After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Propensity Matched Study. Annals of surgery, 274(6), 1009-1016. https://doi.org/10.1097/SLA.0000000000003636
van der Wilk, Berend J, et al. "Active Surveillance Versus Immediate Surgery in Clinically Complete Responders After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Propensity Matched Study." Annals of surgery vol. 274,6 (2021): 1009-1016. doi: https://doi.org/10.1097/SLA.0000000000003636
van der Wilk BJ, Noordman BJ, Neijenhuis LKA, Nieboer D, Nieuwenhuijzen GAP, Sosef MN, Henegouwen MIVB, Lagarde SM, Spaander MCW, Valkema R, Biermann K, Wijnhoven BPL, van der Gaast A, van Lanschot JJB, Doukas M, Nikkessen S, Luyer M, Schoon EJ, Roef MJ, van Lijnschoten I, Oostenbrug LE, Riedl RG, Gisbertz SS, Krishnadath KK, Bennink RJ, Meijer SL. Active Surveillance Versus Immediate Surgery in Clinically Complete Responders After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Propensity Matched Study. Ann Surg. 2021 Dec 01;274(6):1009-1016. doi: 10.1097/SLA.0000000000003636. PMID: 31592898.
Copy Download .nbib Format: NLM
Preferences for active surveillance or standard oesophagectomy: discrete-choice experiment.

The British journal of surgery

van der Wilk BJ, Spronk I, Noordman BJ, Eyck BM, Haagsma JA, Coene PLO, van der Harst E, Heisterkamp J, Lagarde SM, Wijnhoven BPL, van Lanschot JJB.
PMID: 34750625
Br J Surg. 2021 Nov 09; doi: 10.1093/bjs/znab358. Epub 2021 Nov 09.

No abstract available.

Cite
van der Wilk BJ, Spronk I, Noordman BJ, et al. Preferences for active surveillance or standard oesophagectomy: discrete-choice experiment. Br J Surg. 2021;doi: 10.1093/bjs/znab358.
van der Wilk, B. J., Spronk, I., Noordman, B. J., Eyck, B. M., Haagsma, J. A., Coene, P. L. O., van der Harst, E., Heisterkamp, J., Lagarde, S. M., Wijnhoven, B. P. L., & van Lanschot, J. J. B. (2021). Preferences for active surveillance or standard oesophagectomy: discrete-choice experiment. The British journal of surgery, . https://doi.org/10.1093/bjs/znab358
van der Wilk, Berend J, et al. "Preferences for active surveillance or standard oesophagectomy: discrete-choice experiment." The British journal of surgery vol. (2021). doi: https://doi.org/10.1093/bjs/znab358
van der Wilk BJ, Spronk I, Noordman BJ, Eyck BM, Haagsma JA, Coene PLO, van der Harst E, Heisterkamp J, Lagarde SM, Wijnhoven BPL, van Lanschot JJB. Preferences for active surveillance or standard oesophagectomy: discrete-choice experiment. Br J Surg. 2021 Nov 09; doi: 10.1093/bjs/znab358. Epub 2021 Nov 09. PMID: 34750625.
Copy Download .nbib Format: NLM
Lasting Symptoms After Esophageal Resection (LASER): European Multicenter Cross-sectional Study.

Annals of surgery

Markar SR, Zaninotto G, Castoro C, Johar A, Lagergren P, Elliott JA, Gisbertz SS, Mariette C, Alfieri R, Huddy J, Sounderajah V, Pinto E, Scarpa M, Klevebro F, Sunde B, Murphy CF, Greene C, Ravi N, Piessen G, Brenkman H, Ruurda JP, Van Hillegersberg R, Lagarde S, Wijnhoven B, Pera M, Roig J, Castro S, Matthijsen R, Findlay J, Antonowicz S, Maynard N, McCormack O, Ariyarathenam A, Sanders G, Cheong E, Jaunoo S, Allum W, Van Lanschot J, Nilsson M, Reynolds JV, van Berge Henegouwen MI, Hanna GB.
PMID: 32404661
Ann Surg. 2020 Nov 17; doi: 10.1097/SLA.0000000000003917. Epub 2020 Nov 17.

OBJECTIVE: To identify the most prevalent symptoms and those with greatest impact upon health-related quality of life (HRQOL) among esophageal cancer survivors.BACKGROUND: Long-term symptom burden after esophagectomy, and associations with HRQOL, are poorly understood.PATIENTS AND METHODS: Between 2010 and...

Cite
Markar SR, Zaninotto G, Castoro C, et al. Lasting Symptoms After Esophageal Resection (LASER): European Multicenter Cross-sectional Study. Ann Surg. 2020;doi: 10.1097/SLA.0000000000003917.
Markar, S. R., Zaninotto, G., Castoro, C., Johar, A., Lagergren, P., Elliott, J. A., Gisbertz, S. S., Mariette, C., Alfieri, R., Huddy, J., Sounderajah, V., Pinto, E., Scarpa, M., Klevebro, F., Sunde, B., Murphy, C. F., Greene, C., Ravi, N., Piessen, G., Brenkman, H., Ruurda, J. P., Van Hillegersberg, R., Lagarde, S., Wijnhoven, B., Pera, M., Roig, J., Castro, S., Matthijsen, R., Findlay, J., Antonowicz, S., Maynard, N., McCormack, O., Ariyarathenam, A., Sanders, G., Cheong, E., Jaunoo, S., Allum, W., Van Lanschot, J., Nilsson, M., Reynolds, J. V., van Berge Henegouwen, M. I., & Hanna, G. B. (2020). Lasting Symptoms After Esophageal Resection (LASER): European Multicenter Cross-sectional Study. Annals of surgery, . https://doi.org/10.1097/SLA.0000000000003917
Markar, Sheraz R, et al. "Lasting Symptoms After Esophageal Resection (LASER): European Multicenter Cross-sectional Study." Annals of surgery vol. (2020). doi: https://doi.org/10.1097/SLA.0000000000003917
Markar SR, Zaninotto G, Castoro C, Johar A, Lagergren P, Elliott JA, Gisbertz SS, Mariette C, Alfieri R, Huddy J, Sounderajah V, Pinto E, Scarpa M, Klevebro F, Sunde B, Murphy CF, Greene C, Ravi N, Piessen G, Brenkman H, Ruurda JP, Van Hillegersberg R, Lagarde S, Wijnhoven B, Pera M, Roig J, Castro S, Matthijsen R, Findlay J, Antonowicz S, Maynard N, McCormack O, Ariyarathenam A, Sanders G, Cheong E, Jaunoo S, Allum W, Van Lanschot J, Nilsson M, Reynolds JV, van Berge Henegouwen MI, Hanna GB. Lasting Symptoms After Esophageal Resection (LASER): European Multicenter Cross-sectional Study. Ann Surg. 2020 Nov 17; doi: 10.1097/SLA.0000000000003917. Epub 2020 Nov 17. PMID: 32404661.
Copy Download .nbib Format: NLM
Pattern of p53 protein expression is predictive for survival in chemoradiotherapy-naive esophageal adenocarcinoma.

Oncotarget

Ten Kate FJC, Suzuki L, Dorssers LCJ, Dinjens WNM, Jones DTW, Nieboer D, Doukas M, Van Lanschot JJB, Wijnhoven BPL, Looijenga LHJ, Biermann K.
PMID: 29262626
Oncotarget. 2017 Oct 24;8(61):104123-104135. doi: 10.18632/oncotarget.22021. eCollection 2017 Nov 28.

METHODS: In total, 204 chemoradiotherapy (CRT)-naive patients with EAC were included for p53 protein expression evaluation by immunohistochemistry (IHC) on the resection specimens, categorized as overexpression, heterogeneous or loss of expression, and correlated with disease free survival (DFS) and...

Cite
Ten Kate FJC, Suzuki L, Dorssers LCJ, et al. Pattern of p53 protein expression is predictive for survival in chemoradiotherapy-naive esophageal adenocarcinoma. Oncotarget. 2017;8(61):104123-104135doi: 10.18632/oncotarget.22021.
Ten Kate, F. J. C., Suzuki, L., Dorssers, L. C. J., Dinjens, W. N. M., Jones, D. T. W., Nieboer, D., Doukas, M., Van Lanschot, J. J. B., Wijnhoven, B. P. L., Looijenga, L. H. J., & Biermann, K. (2017). Pattern of p53 protein expression is predictive for survival in chemoradiotherapy-naive esophageal adenocarcinoma. Oncotarget, 8(61), 104123-104135. https://doi.org/10.18632/oncotarget.22021
Ten Kate, Fiebo J C, et al. "Pattern of p53 protein expression is predictive for survival in chemoradiotherapy-naive esophageal adenocarcinoma." Oncotarget vol. 8,61 (2017): 104123-104135. doi: https://doi.org/10.18632/oncotarget.22021
Ten Kate FJC, Suzuki L, Dorssers LCJ, Dinjens WNM, Jones DTW, Nieboer D, Doukas M, Van Lanschot JJB, Wijnhoven BPL, Looijenga LHJ, Biermann K. Pattern of p53 protein expression is predictive for survival in chemoradiotherapy-naive esophageal adenocarcinoma. Oncotarget. 2017 Oct 24;8(61):104123-104135. doi: 10.18632/oncotarget.22021. eCollection 2017 Nov 28. PMID: 29262626; PMCID: PMC5732792.
Copy Download .nbib Format: NLM
Fixed Size of Enlarged Calcified Lymph Nodes in Esophageal Adenocarcinoma despite Complete Remission.

Case reports in gastroenterology

Grotenhuis BA, Wijnhoven BP, Hermans JJ, Biermann K, van Lanschot JJ.
PMID: 21103272
Case Rep Gastroenterol. 2009 Jul 03;3(2):182-186. doi: 10.1159/000226253.

Untreated malignant lymph nodes that are calcified are rare. Publications on such calcifications are restricted to case reports. We present a case of calcified lymph nodes in a patient with adenocarcinoma of the gastroesophageal junction that seemed to be...

Cite
Grotenhuis BA, Wijnhoven BP, Hermans JJ, et al. Fixed Size of Enlarged Calcified Lymph Nodes in Esophageal Adenocarcinoma despite Complete Remission. Case Rep Gastroenterol. 2009;3(2):182-186doi: 10.1159/000226253.
Grotenhuis, B. A., Wijnhoven, B. P., Hermans, J. J., Biermann, K., & van Lanschot, J. J. (2009). Fixed Size of Enlarged Calcified Lymph Nodes in Esophageal Adenocarcinoma despite Complete Remission. Case reports in gastroenterology, 3(2), 182-186. https://doi.org/10.1159/000226253
Grotenhuis, B A, et al. "Fixed Size of Enlarged Calcified Lymph Nodes in Esophageal Adenocarcinoma despite Complete Remission." Case reports in gastroenterology vol. 3,2 (2009): 182-186. doi: https://doi.org/10.1159/000226253
Grotenhuis BA, Wijnhoven BP, Hermans JJ, Biermann K, van Lanschot JJ. Fixed Size of Enlarged Calcified Lymph Nodes in Esophageal Adenocarcinoma despite Complete Remission. Case Rep Gastroenterol. 2009 Jul 03;3(2):182-186. doi: 10.1159/000226253. PMID: 21103272; PMCID: PMC2988954.
Copy Download .nbib Format: NLM
Surgery, radiotherapy, and chemotherapy for esophageal carcinoma.

Current opinion in gastroenterology

van Lanschot JJ, González González D, Richel DJ.
PMID: 17031190
Curr Opin Gastroenterol. 2001 Jul;17(4):400-5. doi: 10.1097/00001574-200107000-00017.

Over the last year, several interesting studies have been published on the treatment of esophageal carcinoma. Surprisingly, none of them was a randomized phase III trial. The debate on the necessary extent of a potentially curative surgical resection is...

Cite
van Lanschot JJ, González González D, Richel DJ. Surgery, radiotherapy, and chemotherapy for esophageal carcinoma. Curr Opin Gastroenterol. 2001;17(4):400-5doi: 10.1097/00001574-200107000-00017.
van Lanschot, J. J., González González, D., & Richel, D. J. (2001). Surgery, radiotherapy, and chemotherapy for esophageal carcinoma. Current opinion in gastroenterology, 17(4), 400-5. https://doi.org/10.1097/00001574-200107000-00017
van Lanschot, J J, et al. "Surgery, radiotherapy, and chemotherapy for esophageal carcinoma." Current opinion in gastroenterology vol. 17,4 (2001): 400-5. doi: https://doi.org/10.1097/00001574-200107000-00017
van Lanschot JJ, González González D, Richel DJ. Surgery, radiotherapy, and chemotherapy for esophageal carcinoma. Curr Opin Gastroenterol. 2001 Jul;17(4):400-5. doi: 10.1097/00001574-200107000-00017. PMID: 17031190.
Copy Download .nbib Format: NLM
Patients' perception of diagnostic tests in the preoperative assessment of esophageal cancer.

Patient preference and adherence

Westerterp M, van Westreenen HL, Deutekom M, Stoker J, Fockens P, Comans EF, Plukker JT, Bossuyt PM, van Lanschot JJ, Sloof GW.
PMID: 19920957
Patient Prefer Adherence. 2008 Feb 02;2:157-62.

OBJECTIVE: Defining an optimal staging strategy requires an evaluation of the effectiveness and costs of diagnostic tests and may include the burden of these tests for patients. This study evaluated the burden of cervical ultrasonography (US), endoscopic ultrasonography (EUS),...

Cite
Westerterp M, van Westreenen HL, Deutekom M, et al. Patients' perception of diagnostic tests in the preoperative assessment of esophageal cancer. Patient Prefer Adherence. 2008;2:157-62
Westerterp, M., van Westreenen, H. L., Deutekom, M., Stoker, J., Fockens, P., Comans, E. F., Plukker, J. T., Bossuyt, P. M., van Lanschot, J. J., & Sloof, G. W. (2008). Patients' perception of diagnostic tests in the preoperative assessment of esophageal cancer. Patient preference and adherence, 2157-62.
Westerterp, Marinke, et al. "Patients' perception of diagnostic tests in the preoperative assessment of esophageal cancer." Patient preference and adherence vol. 2 (2008): 157-62.
Westerterp M, van Westreenen HL, Deutekom M, Stoker J, Fockens P, Comans EF, Plukker JT, Bossuyt PM, van Lanschot JJ, Sloof GW. Patients' perception of diagnostic tests in the preoperative assessment of esophageal cancer. Patient Prefer Adherence. 2008 Feb 02;2:157-62. PMID: 19920957; PMCID: PMC2770407.
Copy Download .nbib Format: NLM
Single nucleotide polymorphisms in CRTC1 and BARX1 are associated with esophageal adenocarcinoma.

Journal of carcinogenesis

van Nistelrooij AM, van der Korput HA, Broer L, van Marion R, van Berge Henegouwen MI, van Noesel CJ, Biermann K, Spaander MC, Tilanus HW, van Lanschot JJ, Hofman A, Uitterlinden AG, Wijnhoven BP, Dinjens WN.
PMID: 26085818
J Carcinog. 2015 May 21;14:5. doi: 10.4103/1477-3163.157441. eCollection 2015.

OBJECTIVE: Recently, single nucleotide polymorphisms (SNPs) associated with esophageal adenocarcinoma (EAC) and Barrett's esophagus (BE) were identified; rs10419226 (CRTC1), rs11789015 (BARX1), rs2687201 (FOXP1), rs2178146 (FOXF1), rs3111601 (FOXF1), and rs9936833 (FOXF1). These findings indicate that genetic susceptibility could play a...

Cite
van Nistelrooij AM, van der Korput HA, Broer L, et al. Single nucleotide polymorphisms in CRTC1 and BARX1 are associated with esophageal adenocarcinoma. J Carcinog. 2015;14:5doi: 10.4103/1477-3163.157441.
van Nistelrooij, A. M., van der Korput, H. A., Broer, L., van Marion, R., van Berge Henegouwen, M. I., van Noesel, C. J., Biermann, K., Spaander, M. C., Tilanus, H. W., van Lanschot, J. J., Hofman, A., Uitterlinden, A. G., Wijnhoven, B. P., & Dinjens, W. N. (2015). Single nucleotide polymorphisms in CRTC1 and BARX1 are associated with esophageal adenocarcinoma. Journal of carcinogenesis, 145. https://doi.org/10.4103/1477-3163.157441
van Nistelrooij, Anna M J, et al. "Single nucleotide polymorphisms in CRTC1 and BARX1 are associated with esophageal adenocarcinoma." Journal of carcinogenesis vol. 14 (2015): 5. doi: https://doi.org/10.4103/1477-3163.157441
van Nistelrooij AM, van der Korput HA, Broer L, van Marion R, van Berge Henegouwen MI, van Noesel CJ, Biermann K, Spaander MC, Tilanus HW, van Lanschot JJ, Hofman A, Uitterlinden AG, Wijnhoven BP, Dinjens WN. Single nucleotide polymorphisms in CRTC1 and BARX1 are associated with esophageal adenocarcinoma. J Carcinog. 2015 May 21;14:5. doi: 10.4103/1477-3163.157441. eCollection 2015. PMID: 26085818; PMCID: PMC4453126.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 36 entries